Is your orphan drug approved by regulators but still missing the necessary evidence to satisfy payers? With the average orphan drug today costing $137,782 per person/per yeara, what strategies can ensure reimbursement?
ICON experts recently convened a roundtable to discuss reimbursement and market access issues in rare and orphan disease, specifically how best to identify, obtain and communicate evidence. In Part 1: Identifying Evidence, they share lessons learned from years of orphan drug reimbursement experience:
See how your orphan drug can benefit from the strategic expertise of ICON Commercialisation and Outcomes experts. They deliver multi-disciplinary expertise and strategic insights that integrate health economics, epidemiology, patient-reported outcomes, payer engagement, pricing and market access, to provide compelling evidence for payers.
Part 3: Communicating Evidence - Learn the importance of setting early expectations and strategies for successful evidence communications
Visit www.iconplc.com/rarediseases for more information on ICON’s expertise in Rare and Orphan Disease
aPicavet et al. Shining a light in the black box of orphan drug pricing. Orphanet J Rare Dis. 2014; 9:62